FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug

FDA Denies Approval for Gilead Sciences’ Potential Blockbuster Arthritis Drug

Onlookers had been expecting a thumbs up for filgotinib. Now, that won’t happen for at least another year.

Read More…

You May Also Like